TMH team presents Biocon’s cancer study results at ASCO Annual Meeting 2018
The results of the study conducted across 536 patients in six years clearly show that Nimotuzumab will benefit a large number of…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.